Evaluating biomarkers in transplant recipients to enhance outcomes
Study of Biomarkers in Solid Organ and Bone Marrow Transplant Recipients to Better Treat Rejection
This study is testing if measuring certain proteins in blood and saliva can help doctors understand how well transplant medications are working for people who have received solid organ or bone marrow transplants.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1200 (estimated) |
| Sex | All |
| Sponsor | University of Pittsburgh Academic / other |
| Locations | 1 site (Pittsburgh, Pennsylvania) |
| Trial ID | NCT01163578 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess specific proteins in biological tissues to better understand the effects of drugs used to treat rejection in solid organ and bone marrow transplant recipients. Participants will provide blood and saliva samples during routine clinical tests, allowing for longitudinal analysis of biomarker expression and its correlation with clinical drug concentrations. The study will involve monitoring drug levels and laboratory tests to evaluate immunosuppression adequacy and allograft function over time.
Who should consider this trial
Good fit: Ideal candidates include recipients of abdominal, thoracic, and bone marrow allografts who are undergoing routine follow-up at the University of Pittsburgh Medical Center.
Not a fit: Patients who are unable to read and understand informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management of transplant rejection and better outcomes for transplant recipients.
How similar studies have performed: Other studies have shown promise in using biomarkers to predict transplant outcomes, indicating that this approach has potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Recipients of abdominal, thoracic and bone marrow allografts that are receiving inpatient and outpatient follow-up with routine laboratory tests at the University of Pittsburgh Medical Center. * All Ages * Subject or parents are able to read and understand the informed consent Exclusion Criteria: * Subjects and/or their parents who are unable to read and understand informed consent.
Where this trial is running
Pittsburgh, Pennsylvania
- Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania, United States (Recruiting)
Study contacts
- Principal investigator: Rakesh Sindhi, MD — University of Pittsburgh
- Study coordinator: Morgan L Paul, BSN
- Email: Morgan.Paul2@upmc.edu
- Phone: 412-692-8472
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.